Close Menu

GSK

As part of a lawsuit seeking control of the technology, Santaris has successfully petitioned the European Patent Office to stay its review of Mirrx's patent application.

Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.

While the use of sequencing in disease research for both Mendelian and complex diseases continued to advance during the year, 2010 also saw the launch of several sequencing-based diagnostic tests, as well as pharmaceutical companies entering the sequencing field and the first examples of sequencing being used to make decisions on patient treatment.

Despite the mounting data linking a variety of miRNAs to different diseases, in most cases the data are early-stage, and thus far only a handful of miRNAs have made it into the pipelines of companies in the field.

The agreement calls for the company to apply its mass spec-based phosphoproteomics platform to the study of cell signaling pathways targeted by UCB's therapeutic antibodies and to identify potential protein biomarkers linked to the drugs.

Although OncoMethylome could not disclose the specific drug development program for which its DNA methylation-specific PCR biomarker will be used, GSK's pipeline offers some hints as to the specific immunotherapeutic involved.

Under the agreement, GlaxoSmithKline may use a DNA methylation-specific biomarker developed by OncoMethylome in its immunotherapeutics program.

Pairings: Sep 22, 2010

Premium

Allen Roses, Muin Khoury, Mary Relling, Martin Godbout

Lab21 will offer the service from its UK operations "with immediate effect," and eventually plans to offer the test as part of its comprehensive HIV service at its US facility in Greenville, SC.

Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.